Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Immunopharmacology and Immunotoxicology

Tussilagone suppresses triple-negative breast cancer progression by inhibiting the TLR4/NF-κB pathway and enhancing anti-tumor immunity

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRui HuangHYHao YuZTZhimou Tang

Discussion

Loading...

Member takes

Overview

Experimental analysis reveals that tussilagone decreases tumor progression in triple-negative breast cancer, indicating enhanced anti-tumor immunity.

Key Points

  • Tussilagone significantly inhibits triple-negative breast cancer cell proliferation and invasion.
  • Key evidence shows a dose-dependent reduction in TNBC progression, correlating with TLR4/NF-κB pathway suppression.
  • Assessment utilized cell viability, invasion assays, and co-culture studies to evaluate immune response.
  • Findings highlight tussilagone's promise as a therapeutic candidate in triple-negative breast cancer.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68de8eaeaa6cec72c69ea8ffhttps://doi.org/10.1080/08923973.2025.2555470
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ursolic Acid Inhibits Triple-Negative Breast Cancer Progression by Modulating the FGFR1/AKT/ERK Pathway: Evidence from Network Pharmacology and Experimental Validation2025
  2. 2Effect of Thai traditional formulary medicine on gut microbiota and gene expression profiles in breast cancer cell line-derived xenograft mouse models2025
  3. 3Ameliorative Effects of Tocilizumab on Lung and Liver Metastatic Lesions2025
  4. 4The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting2025
  5. 5Inflammation-associated drug resistance and tumor growth in TNBC2025 · 10 citations